Nutrition Blood Outcomes Following Tocotrienol N2B "NIIB"

Active, not recruiting

Phase N/A Results N/A

Eligibility Criteria

Inclusion Criteria

- Patients with either atherothrombotic, cardioembolic, cryptogenic stroke or TIA (transient ischemic attack) for whom anticoagulation is not indicated
- Enrollment in trial must occur within 6 months of clinical presentation for first stroke or TIA event
- No history of long-term vitamin E supplement (defined as daily oral tocopherol or tocotrienol supplementation at least 6mos; within the past 5 years)
- No current vitamin E supplementation in multi-vitamin

Exclusion Criteria

- Disabling stroke ( Modified Rankin Scale > 3)
- Prior intracranial hemorrhage (excluding traumatic)
- High risk of bleeding (recurrent gastrointestinal, genitourinary bleeding, active peptic ulcer disease)
- Anticipated requirement for long term use of anticoagulation
- Contraindications to antiplatelet agents (bleeding disorder, thrombocytopenia, prolonged INR)
- Irreversible medical condition likely to affect short-term survival or ability to participate in study such as cancer or other chronic disease with predicted survival of less than a year or severe psychiatric or neurologic disease that might complicate evaluation of study outcomes like dementia or schizophrenia
- Pregnancy or women of child bearing age who are not following an effective method of contraception
- Breast feeding
- Unable or unwilling to provide informed
- Unlikely to be compliant with therapy or unwilling to return for follow up frequent clinic visits
- Concurrent participation in another study with an investigational drug or devise
- Other likely specific cause of stroke such as dissection, infectious or noninfectious vasculitis, prothrombotic state